189 related articles for article (PubMed ID: 27618987)
21. Do Patients with Complete Spinal Cord Injury Benefit from Early Surgical Decompression? Analysis of Neurological Improvement in a Prospective Cohort Study.
Bourassa-Moreau É; Mac-Thiong JM; Li A; Ehrmann Feldman D; Gagnon DH; Thompson C; Parent S
J Neurotrauma; 2016 Feb; 33(3):301-6. PubMed ID: 26494114
[TBL] [Abstract][Full Text] [Related]
22. IL-10
Jiang Y; Yang M; Sun X; Chen X; Ma M; Yin X; Qian S; Zhang Z; Fu Y; Liu J; Han X; Xu J; Shang H
BMC Infect Dis; 2018 Feb; 18(1):80. PubMed ID: 29439673
[TBL] [Abstract][Full Text] [Related]
23. The role of timing in the treatment of spinal cord injury.
Saghazadeh A; Rezaei N
Biomed Pharmacother; 2017 Aug; 92():128-139. PubMed ID: 28535416
[TBL] [Abstract][Full Text] [Related]
24. Decreased immune reactivity and neuroendocrine alterations related to chronic stress in spinal cord injury and stroke patients.
Cruse JM; Lewis RE; Bishop GR; Kliesch WF; Gaitan E; Britt R
Pathobiology; 1993; 61(3-4):183-92. PubMed ID: 8216840
[TBL] [Abstract][Full Text] [Related]
25. Restoration of depressed immune function in spinal cord injury patients receiving rehabilitation therapy.
Kliesch WF; Cruse JM; Lewis RE; Bishop GR; Brackin B; Lampton JA
Paraplegia; 1996 Feb; 34(2):82-90. PubMed ID: 8835031
[TBL] [Abstract][Full Text] [Related]
26. Spinal cord injury--incidence, prognosis, and outcome: an analysis of the TraumaRegister DGU.
Stephan K; Huber S; Häberle S; Kanz KG; Bühren V; van Griensven M; Meyer B; Biberthaler P; Lefering R; Huber-Wagner S;
Spine J; 2015 Sep; 15(9):1994-2001. PubMed ID: 25939671
[TBL] [Abstract][Full Text] [Related]
27. Role of Toll like receptor 4 signaling pathway in the secondary damage induced by experimental spinal cord injury.
Impellizzeri D; Ahmad A; Di Paola R; Campolo M; Navarra M; Esposito E; Cuzzocrea S
Immunobiology; 2015 Sep; 220(9):1039-49. PubMed ID: 25990044
[TBL] [Abstract][Full Text] [Related]
28. Lesional Antibody Synthesis and Complement Deposition Associate With De Novo Antineuronal Antibody Synthesis After Spinal Cord Injury.
Schwab JM; Haider C; Kopp MA; Zrzavy T; Endmayr V; Ricken G; Kubista H; Haider T; Liebscher T; Lübstorf T; Blex C; Serdani-Neuhaus L; Curt A; Cinelli P; Scivoletto G; Fehlings MG; May C; Guntermann A; Marcus K; Meisel C; Dirnagl U; Martus P; Prüss H; Popovich PG; Lassmann H; Höftberger R
Neurol Neuroimmunol Neuroinflamm; 2023 May; 10(3):. PubMed ID: 37019668
[TBL] [Abstract][Full Text] [Related]
29. Defining age-related differences in outcome after traumatic spinal cord injury: analysis of a combined, multicenter dataset.
Wilson JR; Davis AM; Kulkarni AV; Kiss A; Frankowski RF; Grossman RG; Fehlings MG
Spine J; 2014 Jul; 14(7):1192-8. PubMed ID: 24210580
[TBL] [Abstract][Full Text] [Related]
30. Predictors of intramedullary lesion expansion rate on MR images of patients with subaxial spinal cord injury.
Le E; Aarabi B; Hersh DS; Shanmuganathan K; Diaz C; Massetti J; Akhtar-Danesh N
J Neurosurg Spine; 2015 Jun; 22(6):611-21. PubMed ID: 25746115
[TBL] [Abstract][Full Text] [Related]
31. Natural killer cells from patients with chronic rhinosinusitis have impaired effector functions.
Kim JH; Kim GE; Cho GS; Kwon HJ; Joo CH; Kim HS; Jang YJ
PLoS One; 2013; 8(10):e77177. PubMed ID: 24204766
[TBL] [Abstract][Full Text] [Related]
32. High frequency of activated natural killer and natural killer T-cells in patients with new onset of type 2 diabetes mellitus.
Guo H; Xu B; Gao L; Sun X; Qu X; Li X; Liu S; Feng J; Wang J; Tang Y; Yan G; Gao X; Jiang Y
Exp Biol Med (Maywood); 2012 May; 237(5):556-62. PubMed ID: 22547395
[TBL] [Abstract][Full Text] [Related]
33. Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection.
Zheng Q; Zhu YY; Chen J; Ye YB; Li JY; Liu YR; Hu ML; Zheng YC; Jiang JJ
Clin Exp Immunol; 2015 Jun; 180(3):499-508. PubMed ID: 25639451
[TBL] [Abstract][Full Text] [Related]
34. Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha.
Marshall JD; Heeke DS; Abbate C; Yee P; Van Nest G
Immunology; 2006 Jan; 117(1):38-46. PubMed ID: 16423039
[TBL] [Abstract][Full Text] [Related]
35. Systemic inflammatory response syndrome in patients with spinal cord injury: does its presence at admission affect patient outcomes? Clinical article.
Kesani AK; Urquhart JC; Bedard N; Leelapattana P; Siddiqi F; Gurr KR; Bailey CS
J Neurosurg Spine; 2014 Aug; 21(2):296-302. PubMed ID: 24836657
[TBL] [Abstract][Full Text] [Related]
36. Long-term functional outcome in patients with acquired infections after acute spinal cord injury.
Kopp MA; Watzlawick R; Martus P; Failli V; Finkenstaedt FW; Chen Y; DeVivo MJ; Dirnagl U; Schwab JM
Neurology; 2017 Feb; 88(9):892-900. PubMed ID: 28130472
[TBL] [Abstract][Full Text] [Related]
37. Results of Early and Late Surgical Decompression and Stabilization for Acute Traumatic Cervical Spinal Cord Injury in Patients with Concomitant Chest Injuries.
Sewell MD; Vachhani K; Alrawi A; Williams R
World Neurosurg; 2018 Oct; 118():e161-e165. PubMed ID: 29959069
[TBL] [Abstract][Full Text] [Related]
38. Multicenter prospective nonrandomized controlled clinical trial to prove neurotherapeutic effects of granulocyte colony-stimulating factor for acute spinal cord injury: analyses of follow-up cases after at least 1 year.
Inada T; Takahashi H; Yamazaki M; Okawa A; Sakuma T; Kato K; Hashimoto M; Hayashi K; Furuya T; Fujiyoshi T; Kawabe J; Mannoji C; Miyashita T; Kadota R; Someya Y; Ikeda O; Hashimoto M; Suda K; Kajino T; Ueda H; Ito Y; Ueta T; Hanaoka H; Takahashi K; Koda M
Spine (Phila Pa 1976); 2014 Feb; 39(3):213-9. PubMed ID: 24299727
[TBL] [Abstract][Full Text] [Related]
39. Immune depression syndrome following human spinal cord injury (SCI): a pilot study.
Riegger T; Conrad S; Schluesener HJ; Kaps HP; Badke A; Baron C; Gerstein J; Dietz K; Abdizahdeh M; Schwab JM
Neuroscience; 2009 Feb; 158(3):1194-9. PubMed ID: 18790013
[TBL] [Abstract][Full Text] [Related]
40. N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulation.
Ciaglia E; Pisanti S; Picardi P; Laezza C; Malfitano AM; D'Alessandro A; Gazzerro P; Vitale M; Carbone E; Bifulco M
J Leukoc Biol; 2013 Dec; 94(6):1207-19. PubMed ID: 23847096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
